Leading domestic pharmaceutical equipment industry, performance is expected to usher in a period of continuous growth

In recent years, influenced by the continuous release of favorable policies for the pharmaceutical industry and the pharmaceutical industry, the development of the entire pharmaceutical equipment industry has also begun to usher in more new opportunities
.
Among them, it is particularly worth mentioning that the performance of some pharmaceutical machinery companies has significantly increased
.
The performance of pharmaceutical machinery companies is expected to usher in a period of continuous growth (picture source: Pharmaceutical Network) For example, in the first half of the year, many pharmaceutical machinery companies have shown that their performance has doubled in their semi-annual reports
.
For example, Chutian Technology made a profit of approximately 236 million yuan in the first half of 2021, a year-on-year increase of 1321.
22%; Tofflon achieved operating income of 1.
81 billion yuan, a year-on-year increase of 52.
22%; while Xinlai made a profit of approximately 67.
89 million yuan, a year-on-year increase of 101.
1%.

.
The industry predicts that in the context of the favorable pharmaceutical environment, the continuous optimization of the pharmaceutical competition pattern and the continuous increase of market concentration, the profitability of pharmaceutical equipment companies will gradually increase in the future
.
There are two main reasons for this conclusion: First, in the long run, due to the large demand potential of China's pharmaceutical industry, and the new version of the "Administrative Measures for Drug Registration" cancels GMP certification, and instead strengthens the entire process of drug production.
With the dynamic supervision of the whole life cycle of medicines, the demand for pharmaceutical equipment is expected to be released steadily in the future, and the industry is expected to transform from short-term explosive growth to long-term steady growth
.
In addition, the current process of replacing imports with domestic products has also begun to accelerate under the support of the policy of preferential procurement of domestically-produced equipment
.
In this regard, industry analysts believe that under the background that the domestic pharmaceutical industry continues to develop in a high-quality direction through innovation and upgrading, in the future, more and more domestic pharmaceutical equipment companies will continue to increase their overseas revenue market and gain more overseas customers.
Favor and praise
.
On the whole, as the pharmaceutical equipment market enters the growth period of overall stability and partial breakthroughs; and with the recovery of the upstream pharmaceutical industry, a large number of Chinese pharmaceutical equipment companies will benefit, and their performance may also have new breakthroughs
.
Take Tofflon as an example.
In fact, Kaiyuan Securities previously stated that Tofflon is one of the leaders in the domestic pharmaceutical equipment industry.
Benefiting from the coming of the industry’s turning point, it believes that the company’s revenue is expected to maintain steady growth in the future and its profitability will gradually increase.

.
It is worth mentioning that while optimistic about the company’s long-term development potential, it also predicts that Teflon will achieve a net profit of 2.
51/3.
23/405 billion yuan attributable to its parent in 2020/2021/2022, a year-on-year increase of 72.
5%/28.
4%/25.
3.
%
.
In general, with the advancement of a series of new medical reform systems, the pharmaceutical equipment industry is constantly being updated and upgraded, and the market scale is also expanding
.
In this context, pharmaceutical machinery companies will also have more development opportunities
.
However, it should be noted that as industry competition intensifies and the public pays more attention to drug safety, pharmaceutical companies will also place higher demands on the pharmaceutical equipment industry on the safety, production efficiency, and stability of pharmaceutical equipment.

.
In this regard, only by accelerating technological innovation and accelerating development towards intelligence, digitization and industrialization can pharmaceutical machinery companies improve the manufacturing level and production capacity of China’s pharmaceutical equipment at a higher level and on a larger scale, while meeting the needs of various companies.
, Usher in its own continuous and positive development
.